Day One Biopharma gains on FDA's accelerated nod for brain tumor treatment

Day One Biopharmaceuticals

23/04/2024 19:59

** Shares of Day One Biopharmaceuticals  DAWN.O  rise 10.2%
to $16.94 
    ** U.S. FDA on Tuesday granted accelerated approval to
DAWN's monotherapy in treating patients 6 months of age and
older with a type of brain tumor 
    ** The therapy, called Tovorafenib, will require
confirmatory trials to receive the FDA's traditional approval 
    ** The regulator's nod allows use as a once-weekly
monotherapy in patients with types of pediatric low-grade
glioma, which are slow-growing brain tumors
    ** YTD stock up ~16%, including session's gain

 (Reporting by Pratik Jain in Bengaluru)
 ((Pratik.Jain@thomsonreuters.com;))